China SXT Pharmaceuticals (NASDAQ:SXTC) Shares Down 2.1% – Time to Sell?

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) dropped 2.1% during trading on Monday . The company traded as low as $1.4001 and last traded at $1.41. Approximately 35,249 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 316,497 shares. The stock had previously closed at $1.44.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

China SXT Pharmaceuticals Price Performance

The company has a quick ratio of 3.40, a current ratio of 3.54 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $1.59.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in China SXT Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 48,759 shares of the company’s stock, valued at approximately $78,000. 5.02% of the stock is owned by institutional investors and hedge funds.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.